EGFR and neoplasm: For example the mutational status of EGFR can be readily detected in primary tumors and the correlation between EGFR mutations and EGFR TKI (Tyrosine Kinase Inhibitors) sensitivity has been validated in several clinical trials, but it may be difficult to obtain tumor tissues for such analysis.